Uno studio su zipalertinib e chemioterapia rispetto alla sola chemioterapia in pazienti con carcinoma polmonare avanzato non a piccole cellule con inserzione dell'esone 20 del recettore del fattore di crescita epidermico (EGFR). (REZILIENT3)
Studio multicentrico globale, randomizzato, controllato, in aperto, di fase 3 per valutare l'efficacia e la sicurezza di Zipalertinib più chemioterapia rispetto alla sola chemioterapia, in pazienti con carcinoma polmonare non a piccole cellule non squamoso (NSCLC) precedentemente non trattato, localmente avanzato o metastatico Con mutazioni di inserzione dell'esone 20 (ex20ins) del recettore del fattore di crescita epidermico (EGFR)
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This study will evaluate the efficacy and safety of zipalertinib in combination with standard chemotherapy with pemetrexed and a platinum agent (either carboplatin or cisplatin) in patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC harboring EGFR ex20ins mutations.
The study will be conducted in two parts:
- Part A: Safety lead-in to determine the recommended dose of zipalertinib in combination with standard chemotherapy pemetrexed and a platinum agent (either carboplatin or cisplatin) to be studied in Part B of the study.
- Part B: Randomized, controlled, open-label, multinational Phase 3 study to assess the efficacy and safety of zipalertinib in combination with standard chemotherapy with pemetrexed and a platinum agent (either carboplatin or cisplatin) compared to standard chemotherapy alone. Patients randomized to the chemotherapy-only treatment arm in Part B may receive treatment with zipalertinib as monotherapy after BICR-assessed progressive disease (PD) is documented (optional "crossover arm").
An independent data monitoring committee (IDMC) will be established to monitor interim safety Data.
A treatment cycle is defined as 21 days for both parts of the study.
Part A: Safety Lead-In The primary objective of Part A is to determine the recommended dose of zipalertinib administered in combination with pemetrexed and a platinum agent (either carboplatin or cisplatin) to be studied in the Phase 3 portion of this study.
Approximately 6-12 patients will receive zipalertinib administered at an initial dose of zipalertinib PO BID (Dose Level 1) in combination with pemetrexed and carboplatin or cisplatin on a 21-day cycle. Patients may continue to receive study treatment until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first. Patients will be enrolled using a rolling-6 design,35 and the determination of the dose of zipalertinib to be used in Part B of the study will be informed by the incidence of dose-limiting toxicities (DLTs) observed during Cycle 1.
Part B: Phase 3 Enrollment into the Phase 3 portion of the study will begin following completion of Part A.
Approximately 260 patients will be randomized on a 1:1 basis to receive pemetrexed and a platinum agent (either carboplatin or cisplatin) with or without zipalertinib on a 21-day cycle.
Carboplatin or cisplatin will be administered for 4 cycles. Patients may continue to receive zipalertinib (experimental study arm) and pemetrexed (both study arms) until documentation of PD or until other withdrawal criteria are met, whichever comes first.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, Belgio, 3000
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg
-
-
Oost-Vlaaderen
-
Ghent, Oost-Vlaaderen, Belgio, 9000
- Algemeen Ziekenhuis Maria Middelares
-
-
West Flanders
-
Menen, West Flanders, Belgio, 8930
- Algemeen Ziekenhuis Delta - Campus Menen
-
-
West-Vlaanderen
-
Rosières, West-Vlaanderen, Belgio, 8800
- Algemeen Ziekenhuis Delta - Campus Rumbeke
-
-
-
-
Ceará
-
Fortaleza, Ceará, Brasile, 60335-480
- Centro Regional Integrado de Oncologia
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasile, 90110-270
- Hospital Mãe de Deus - Centro Integrado de Oncologia
-
Porto Alegre, Rio Grande do Sul, Brasile, 90610-000
- Hospital São Lucas da PUCRS
-
-
Santa Catatina
-
Itajaí, Santa Catatina, Brasile, 88301
- Clínica Neoplasias Litoral
-
-
São Paulo
-
Jaú, São Paulo, Brasile, 17210-180
- Hospital Amaral Carvalho
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BC Cancer Vancouver
-
-
Ontario
-
Brampton, Ontario, Canada, L6R 3J7
- William Osler Health System - Brampton Civic Hospital
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Cancer Centre
-
-
-
-
Region de Santiago
-
Santiago, Region de Santiago, Chile, 7500653
- CentroEstudiosClinicosSAGA
-
-
Santiago Metropolitan
-
Independencia, Santiago Metropolitan, Chile, 8380494
- Hospital Clínico Universidad de Chile
-
-
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Corea del Sud
- Seoul National University Bundang Hospital
-
Suwon, Gyeonggi-do, Corea del Sud, 16499
- Ajou University Hospital
-
Suwon, Gyeonggi-do, Corea del Sud, 16247
- Catholic University of Korea Saint Vincent's Hospital
-
-
Gyeongsangnamdo [Kyongsangnam-do]
-
Jinju, Gyeongsangnamdo [Kyongsangnam-do], Corea del Sud, 52727
- Gyeongsang National University Hospital
-
-
Incheon Gwang'yeogsi [Inch'on-Kwangyokshi]
-
Incheon, Incheon Gwang'yeogsi [Inch'on-Kwangyokshi], Corea del Sud, 22332
- Inha University Hospital
-
-
Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Corea del Sud, 02841
- Korea University Anam Hospital
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Corea del Sud, 08308
- Korea University Guro Hospital
-
-
-
-
-
City of Muntinlupa, Filippine, 1780
- Asian Hospital and Medical Center
-
-
Metropolitan Manila
-
Quezon City, Metropolitan Manila, Filippine, 1112
- St. Luke's Medical Center - Quezon City
-
-
National Capital Region
-
Pasig, National Capital Region, Filippine, 1605
- The Medical City
-
-
-
-
-
Quimper, Francia, 29000
- CH Cornouaille Quimper
-
-
Alsace
-
Strasbourg, Alsace, Francia, 67091
- Les Hôpitaux Universitaires de Strasbourg
-
-
Basse-Normandie
-
Caen, Basse-Normandie, Francia, 14033
- Hôpital Côte De Nacre
-
-
Limousin
-
Limoges, Limousin, Francia, 87042
- Centre Hospitalier Universitaire Limoges
-
-
Île-de-France Region
-
Boulogne-Billancourt, Île-de-France Region, Francia, 92100
- Hôpital Ambroise-Paré
-
Paris, Île-de-France Region, Francia, 75248
- Institut Curie
-
-
-
-
-
München, Germania, 80337
- LMU Klinikum - Campus Innenstadt
-
Regensburg, Germania, 93053
- Universitätsklinikum Regensburg
-
-
Hesse
-
Giessen, Hesse, Germania, 35392
- Universitätsklinikum Gießen und Marburg - Gießen
-
-
-
-
-
Kanazawa, Giappone, 920-8641
- Kanazawa University Hospital
-
Osaka, Giappone, 534-0021
- Osaka City General Hospital
-
Osaka, Giappone, 541-8567
- Osaka Prefectural Hospital Organization - Osaka International Cancer Institute
-
-
Aiti [Aichi]
-
Nagoya, Aiti [Aichi], Giappone, 464-8681
- Aichi Cancer Center
-
-
Aomori
-
Hirosaki-Shi, Aomori, Giappone, 036-8563
- Hirosaki University Hospital
-
-
Hukuoka
-
Fukuoka, Hukuoka, Giappone, 811-1395
- Kyushu Cancer Center
-
-
Kanagawa
-
Sagamihara, Kanagawa, Giappone, 252-0375
- Kitasato University Hospital
-
-
Kumamoto
-
Kumamoto, Kumamoto, Giappone, 861-4163
- Saiseikai Kumamoto Hospital
-
-
Miyagi
-
Sendai, Miyagi, Giappone, 980-0873
- Sendai Kousei Hospital
-
-
Okayama-ken
-
Okayama, Okayama-ken, Giappone, 700-8558
- Okayama University Hospital
-
-
Osaka
-
Hirakata, Osaka, Giappone, 573-1191
- Kansai Medical University Hospital
-
Sakai-Shi, Osaka, Giappone, 591-8555
- National Hospital Organization Kinki-Chuo Chest Medical Center
-
-
Tokyo
-
Koto, Tokyo, Giappone, 135-8550
- Cancer Institute Hospital of JFCR
-
Shinjuku-Ku, Tokyo, Giappone, 160-8582
- Keio University Hospital
-
-
-
-
Attica
-
Athens, Attica, Grecia, 11527
- General Hospital for Thoracic Diseases Sotiria
-
-
-
-
-
Afula, Israele, 18101
- Emek Medical Center
-
Jerusalem, Israele, 9103102
- Shaare Zedek Medical Center
-
Tel Aviv, Israele, 69710
- Assuta Hospital - Ramat HaHayal
-
-
-
-
-
Milan, Italia, 20132
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele
-
Modena, Italia, 41224
- Azienda Ospedaliero - Universitaria di Modena
-
Pavia, Italia, 27100
- Fondazione IRCCS Policlinico San Matteo
-
Ravenna, Italia, 48121
- Azienda Unità Sanitaria Locale della Romagna
-
Roma, Italia, 1444
- IRCCS Istituto Nazionale Tumori Regina Elena
-
Verona, Italia, 37126
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Italia, 47014
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
-
-
Forlì-Cesena
-
Meldola, Forlì-Cesena, Italia, 47014
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
-
-
Genoa
-
Genova, Genoa, Italia, 16132
- Istituto Nazionale per la Ricerca sul Cancro
-
-
-
-
-
Aguascalientes, Messico, 20124
- Investigacion Medica Galerias
-
Veracruz, Messico, 91900
- FAICIC Clínical Research
-
-
Jalisco
-
Guadalajara, Jalisco, Messico, 44280
- Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"
-
Guadalajara, Jalisco, Messico, 44680
- Actualidad Basada en la Investigación del Cáncer
-
-
Mexico City
-
Mexico City, Mexico City, Messico, 3100
- Health Pharma Professional Research S.A. De C.V
-
-
Puebla
-
Mirador, Puebla, Messico, 72530
- Clínica Integral Internacional de Oncología S de RL de CV
-
-
-
-
Gelderland
-
Nijmegen, Gelderland, Olanda, 6525 GA
- Radboud Universitair Medisch Centrum
-
-
North Holland
-
Amsterdam, North Holland, Olanda, 1066 CX
- Antoni Van Leeuwenhoek Ziekenhuis
-
Amsterdam, North Holland, Olanda, 1081 HV
- Vrije Universiteit Medisch Centrum
-
-
-
-
Greater Poland Voivodeship
-
Pozna?, Greater Poland Voivodeship, Polonia, 60-569
- Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polonia, 20-954
- Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
-
-
Lódzkie
-
Lodz, Lódzkie, Polonia, 90-302
- Instytut MSF
-
-
-
-
England
-
London, England, Regno Unito, NW3 2QG
- Royal Free London NHS Foundation Trust
-
Nottingham, England, Regno Unito, NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Torquay, England, Regno Unito, TQ2 7AA
- Torbay and South Devon NHS Foundation Trust
-
-
-
-
-
Suceava, Romania, 720214
- Clinica SIGMedical
-
-
Dolj
-
Craiova, Dolj, Romania, 200746
- Centrul de Oncologie Sf Nectarie
-
-
-
-
-
Singapore, Singapore, 168583
- National Cancer Centre Singapore
-
Singapore, Singapore, 228510
- Icon Cancer Centre - Mount Alvernia
-
Singapore, Singapore, 30433
- Tan Tock Seng Hospital
-
Singapore, Singapore, 574623
- Icon Cancer Centre Mount Elizabeth
-
Singapore, Singapore, 308900
- Oncocare Cancer Centre
-
-
-
-
-
Barcelona, Spagna, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Spagna, 08017
- Clínica Mi Tres Torres
-
Barcelona, Spagna, 08023
- Hospital Quirónsalud Barcelona
-
Jaén, Spagna, 23007
- Hospital Universitario de Jaén
-
Madrid, Spagna, 28040
- Hospital Universitario Fundación Jiménez Díaz
-
Madrid, Spagna, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spagna, 28046
- Hospital Universitario La Paz
-
Málaga, Spagna, 29010
- Hospital Regional Universitario de Málaga - Hospital General
-
-
La Coruña
-
A Coruña, La Coruña, Spagna, 15006
- Complejo Hospitalario Universitario A Coruña
-
-
-
-
Nevada
-
Henderson, Nevada, Stati Uniti, 89052
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Stati Uniti, 89074
- Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie
-
Las Vegas, Nevada, Stati Uniti, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley - Twain
-
Las Vegas, Nevada, Stati Uniti, 89144
- Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II
-
Las Vegas, Nevada, Stati Uniti, 89148
- Comprehensive Cancer Centers of Nevada - Southwest
-
Las Vegas, Nevada, Stati Uniti, 89218
- Comprehensive Cancer Centers of Nevada - Northwest
-
-
Ohio
-
Canton, Ohio, Stati Uniti, 44718
- Gabrail Cancer and Research Center
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- University of Texas MD Anderson Cancer Center
-
-
-
-
Bangkok
-
Bang Phlat, Bangkok, Tailandia, 10700
- Faculty of Medicine Siriraj Hospital
-
Pathum Wan, Bangkok, Tailandia, 10330
- King Chulalongkorn Memorial Hospital
-
-
Khet Dusit
-
Bangkok, Khet Dusit, Tailandia, 10300
- Navamindradhiraj University - Faculty of Medicine Vajira Hospital
-
-
-
-
-
Adana, Turchia (Türkiye), 01120
- Medical Park Seyhan Hastanesi
-
Ankara, Turchia (Türkiye), 6520
- Memorial Ankara Hastanesi
-
Ankara, Turchia (Türkiye), 06010
- Hacettepe Üniversitesi Kanser Enstitüsü
-
Edirne, Turchia (Türkiye), 22130
- Trakya Üniversitesi Sa?l?k Ara?t?rma ve Uygulama Merkezi
-
Etlik, Turchia (Türkiye), 06010
- Ankara Il Saglik Mudurlugu SBU Gulhane Egitim Ve Arastirma Hastanesi
-
Istanbul, Turchia (Türkiye), 34214
- Bagcilar Medipol Mega Universite Hastanesi
-
Istanbul, Turchia (Türkiye), 34722
- T.C. Saglik Bakanligi - Istanbul Il Saglik Mudurlugu - Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
-
Çankaya, Turchia (Türkiye), 06800
- T.C. Saglik Bakanligi Ankara Bilkent Sehi?r Hastanesi?
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion-
-
Provide written informed consent.
-
≥18 years of age (or meets the country's regulatory definition for legal adult age, whichever is greater).
-
Pathologically confirmed, locally advanced or metastatic nonsquamous NSCLC
-
Has not received any prior systemic treatment for their locally advanced or metastatic nonsquamous NSCLC. Prior adjuvant/neoadjuvant treatment received >6 months prior to first dose of study treatment is allowed for early-stage
NSCLC. Prior monotherapy with an approved EGFR TKI (ie, gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib) as nonstandard first-line therapy for the treatment of locally advanced or metastatic disease is allowed if all of the following criteria are met:
- Treatment duration did not exceed 8 weeks;
- Lack of disease response was documented (radiographically) by an increase in tumor burden (a copy of the computerized tomography [CT] report showing increase in tumor burden from baseline should be submitted);
- Associated toxicities have resolved to baseline; and
- The EGFR TKI was discontinued at least 2 weeks or 4 half-lives prior to randomization, whichever is longer.
Prior therapy with EGFR TKI agents targeting exon20ins mutations including amivantamab, mobocertinib, sunvozertinib, furmonertinib, and poziotinib is not allowed.
-
Documented EGFR mutation status, as determined by local testing performed at a CLIA certified (US) or accredited (outside of the US) local laboratory, defined as follows:
- Part A: EGFR ex20ins or other uncommon single or compound EGFR mutation
- Part B: EGFR ex20ins mutation
-
Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFR mutation status and, where possible, other biomarkers. Patients with insufficient tissue (details provided in laboratory manual) may be eligible following discussion with the sponsor; a fresh biopsy will not be required.
-
Patients with brain metastasis(es) who have previously received definitive local treatment and have stable central nervous system (CNS) disease (defined as being neurologically stable and off corticosteroid for at least 2 weeks prior to enrollment) are eligible. If brain metastases are diagnosed on screening imaging, the patient may be rescreened for eligibility after definitive treatment.
b. Asymptomatic brain metastases ≤2 cm in size can be eligible for inclusion if, in the opinion of the Investigator, immediate definitive treatment is not indicated.
-
At least one measurable lesion as determined per RECIST 1.1 for patients enrolling to Part B. Patients enrolling to Part A may be enrolled without measurable disease.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
-
Adequate organ function, as defined by the laboratory value
-
Have a life expectancy of at least 3 months as assessed by the investigator.
-
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female patients are not considered to be of childbearing potential if they are postmenopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
-
Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose and for 6 months after the last dose of study treatment or longer, based on local requirements.
Exclusion -
-
Is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study.
-
Prior treatment with any of the following within the specific time frame specified:
- Zipalertinib (TAS6417/CLN-081) at any time.
- Thoracic radiotherapy ≤28 days, palliative radiation of nonthoracic disease ≤14 days, or palliative radiation of a single lesion ≤7 days prior to first dose of study treatment.
- Major surgery (excluding placement of vascular access) ≤28 days prior to first dose of study treatment.
- All prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications that are strong or moderate CYP3A4 inducers or inhibitors within 7 days prior to first dose.
-
Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment in the neoadjuvant or adjuvant setting, except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor.
-
Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or any evidence of clinically active interstitial lung disease.
-
Impaired cardiac function or clinically significant cardiac disease, including any of the following:
- History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification .
- Serious cardiac arrhythmias requiring treatment.
- Resting corrected QT interval (QTc) >470 msec calculated using Fridericia's formula (QTcF).
-
Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior GI resection).
-
History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:
- Adequately treated basal or squamous cell carcinoma of the skin
- Cancer of the breast or cervix in situ
- Previously treated malignancy, if all treatment for that malignancy was completed at least 2 years prior to first dose of study treatment, and no current evidence of disease
- Concurrent malignancy determined to be clinically stable and not requiring tumor directed treatment
-
Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is unstable or not controlled with treatment.
-
History of COVID-19 infection within 4 weeks prior to enrolment and/or have persistent, clinically significant pulmonary symptoms related to prior COVID-19 infection.
-
Active bleeding disorders.
-
Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class. To platinum-containing drugs (ie, cisplatin, carboplatin), pemetrexed, or any known excipients of these drugs. b. Contraindications toning drugs (ie, cisplatin, carboplatin) or pemetrexed according to the respective local labels.
-
History of leptomeningeal disease and spinal cord compression.
-
Is unable or unwilling to take dexamethasone, folic acid, and/or vitamin B12 supplementation during treatment with pemetrexed.
-
Is pregnant or lactating or planning to become pregnant
-
The patient is, in the investigator's opinion, unable or unwilling to comply with the trial procedures.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Part A (Safety Lead in)
Part A: Safety Lead-In Approximately 6-12 patients will receive zipalertinib administered at an initial dose of zipalertinib PO BID (Dose Level 1) in combination with pemetrexed and carboplatin or cisplatin on a 21-day cycle. Patients may continue to receive study treatment until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first. |
oral tablets
Altri nomi:
|
|
Sperimentale: Part B
Enrollment into the Phase 3 portion of the study will begin following completion of Part A. Approximately 260 patients will be randomized on a 1:1 basis to receive pemetrexed and a platinum agent (either carboplatin or cisplatin) with or without zipalertinib on a 21-day cycle. Carboplatin or cisplatin will be administered for 4 cycles. Patients may continue to receive zipalertinib (experimental study arm) and pemetrexed (both study arms) until documentation of PD or until other withdrawal criteria are met, whichever comes first. |
oral tablets
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Parte A e B: tasso e gravità degli eventi avversi insorti durante il trattamento
Lasso di tempo: circa 5 anni
|
circa 5 anni
|
|
Parte A e Parte B: Sopravvivenza libera da progressione (PFS) mediante revisione centrale indipendente in cieco (BICR)
Lasso di tempo: circa 5 anni
|
circa 5 anni
|
|
Parte A: Il tasso e la gravità delle DLT secondo i criteri di terminologia comune degli eventi avversi (CTCAE) v5.0 dell'NCI durante il Ciclo 1
Lasso di tempo: circa 5 anni
|
circa 5 anni
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Parte A e Parte B: Tasso di risposta obiettiva (ORR)
Lasso di tempo: circa 5 anni
|
circa 5 anni
|
|
|
Parte A e Parte B: tasso di controllo delle malattie (DCR)
Lasso di tempo: circa 5 anni
|
circa 5 anni
|
|
|
Parte A e Parte B: Durata della risposta (DoR)
Lasso di tempo: circa 5 anni
|
circa 5 anni
|
|
|
Parte A e Parte B: Tasso di risposta globale intracranico (i) (iORR)
Lasso di tempo: circa 5 anni
|
circa 5 anni
|
|
|
Parte A e Parte B: durata intracranica della risposta completa (iDCR)
Lasso di tempo: circa 5 anni
|
circa 5 anni
|
|
|
Parte A e Parte B: durata della risposta intracranica (iDoR)
Lasso di tempo: circa 5 anni
|
circa 5 anni
|
|
|
Parte B: Sopravvivenza globale (OS)
Lasso di tempo: circa 5 anni
|
circa 5 anni
|
|
|
Pharmacokinetic (PK) parameter
Lasso di tempo: approximately 5 years
|
Minimum observed concentration (Cmin) |
approximately 5 years
|
|
European Quality of Life 5 Dimensions, 3 Level Version (EQ-5D-3L)
Lasso di tempo: approximately 5 years
|
The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. This scale is numbered from 0 to 100. The higher the score the better the outcome |
approximately 5 years
|
|
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30
Lasso di tempo: approximately 5 years
|
The EORTC QLQ-C30 is a "core questionnaire" which incorporates a range of physical, emotional and social health developed to assess the quality of life of cancer patients. This scale is numbered from 30 to 130. The higher the score equates to better functioning. |
approximately 5 years
|
|
Non-small Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ )
Lasso di tempo: approximately 5 years
|
The NSCLC- SAQ was developed to incorporate the patient's perspective into evaluation of clinical benefit in advanced non-small cell lung cancer trials.. Qualitative evidence supports 7 items covering 5 symptom concepts with the total score measuring overall severity of the following NSCLC symptoms: cough, pain, dyspnea, fatigue, and appetite. Lower scores indicate lower symptom severity. |
approximately 5 years
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pharmacokinetic (PK) parameter
Lasso di tempo: approximately 5 years
|
Minimum Plasma Concentration [Cmin] |
approximately 5 years
|
|
Pharmacokinetic (PK) parameter
Lasso di tempo: approximately 5 years
|
Maximum Plasma Concentration [Cmax] |
approximately 5 years
|
|
Pharmacokinetic (PK) parameter
Lasso di tempo: approximately 5 years
|
Area Under Curve [AUC] |
approximately 5 years
|
|
EGFR mutation status
Lasso di tempo: approximately 5 years
|
local central tests results |
approximately 5 years
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- TAS6417-301
- 2023-503575-21 (Numero EudraCT)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .